HomeHealth

Health

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

August 25, 2026

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

August 22, 2026

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 22, 2026

Aveanna Announces Pricing of Secondary Offering of Common Stock

Aveanna Announces Pricing of Secondary Offering of Common Stock

August 21, 2026

HealthTab™ Enters Multi-Year Collaboration Agreement with Abbott for Point-of-Care Testing Across the UK

HealthTab™ Enters Multi-Year Collaboration Agreement with Abbott for Point-of-Care Testing Across the UK

August 20, 2026

Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

August 20, 2026

Six-month interim report (Q2) 2026 (unaudited)

Six-month interim report (Q2) 2026 (unaudited)

August 20, 2026

ALK appoints Jacob Glenting as head of Global R&D

ALK appoints Jacob Glenting as head of Global R&D

August 20, 2026

So-Young to Report Second Quarter 2026 Financial Results on August 31, 2026

So-Young to Report Second Quarter 2026 Financial Results on August 31, 2026

August 19, 2026

Haleon plc: Announces Pricing Terms, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes

Haleon plc: Announces Pricing Terms, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes

August 19, 2026

« 1 … 3 4 5 6 7 … 220 »